

In the Claims:

Please cancel claims 5-12, 19, and 20.

Please amend the claims to read as follows:

D1  
C2  
21. (amended) A composition for inducing an immune response in a subject, comprising at least one purified peptide comprising at least 10 contiguous amino acids of an amino acid sequence as set forth as SEQ ID NO: 8 or SEQ ID NO: 14.

Please cancel claim 22.

23. (reiterated) The composition of claim 21 wherein the sequence of the at least one peptide comprises at least 15 contiguous amino acids of at least one of the specified sequences.

24. (reiterated) The composition of claim 21 wherein the sequence of the at least one peptide comprises at least 20 contiguous amino acids of at least one of the specified sequences.

25. (reiterated) A composition for inducing an immune response comprising at least one purified peptide comprising an amino acid sequence as set forth as SEQ ID NO: 8 or SEQ ID NO: 14.

D1  
C3  
26. (amended) A method of making a composition for inducing an immune response in a mammal comprising combining a pharmaceutically acceptable excipient with at least one purified peptide having an amino acid sequence as set forth as SEQ ID NO: 8 or SEQ ID NO: 14.

27. (reiterated) A method of inducing an immune response in a subject, comprising administering a composition according to claim 21 to a mammal.

28. (reiterated) A method of inducing an immune response in a subject, comprising administering a composition according to claim 24 to a mammal.

29. (reiterated) The method of claim 26, wherein the mammal is a human.

30. (reiterated) The method of claim 27, wherein the mammal is a human.

*Please add the following new claims:*

31. (new) A method of inducing an immune response in a subject, comprising administering a composition according to claim 23 to a mammal.

32. (new) The method of claim 31, wherein the mammal is a human.

33. (new) The method of claim 28, wherein the mammal is a human.

34. (new) A method of inducing an immune response in a subject, comprising administering a composition according to claim 25 to a mammal.

35. (new) The method of claim 34, wherein the mammal is a human.

36. (new) The composition of claim 21 wherein the sequence of the at least one peptide comprises at least 25 contiguous amino acids of at least one of the specified sequences.

37. (new) A method of inducing an immune response in a subject, comprising administering a composition according to claim 36 to a mammal.

38. (new) The method of claim 37, wherein the mammal is a human.

39. (new) The composition of claim 21 wherein the sequence of the at least one peptide comprises at least 30 contiguous amino acids of at least one of the specified sequences.

40. (new) A method of inducing an immune response in a subject, comprising administering a composition according to claim 39 to a mammal.
41. (new) The method of claim 40, wherein the mammal is a human.
42. (new) The composition of claim 21 wherein the sequence of the at least one peptide comprises at least 40 contiguous amino acids of at least one of the specified sequences.
43. (new) A method of inducing an immune response in a subject, comprising administering a composition according to claim 42 to a mammal.
44. (new) The method of claim 43, wherein the mammal is a human.
45. (new) The composition of claim 21 wherein the sequence of the at least one peptide comprises at least 45 contiguous amino acids of at least one of the specified sequences.
46. (new) A method of inducing an immune response in a subject, comprising administering a composition according to claim 34 to a mammal.
47. (new) The method of claim 46, wherein the mammal is a human.

#### REMARKS

Claims 5-12 and 19-30 were pending in this application. By this amendment, claims 5-12, 19, 20, and 22 are canceled. Applicants expressly reserve the right to pursue protection of any or all of the subject matter in the canceled claims in a subsequent application. In addition, claims 23-30 remain in the application without amendment, claims 21 and 26 are amended, and claims 31-47 are added. Claim 26 is amended hereby to provide antecedent basis for reiterated claim 29 by specifying that the immune response is induced in a mammal. Support for this amendment can be found at least at page 16, lines 25-26 of the specification. No new matter has